Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add filters








Year range
1.
Chinese Journal of Natural Medicines (English Ed.) ; (6): 352-363, 2022.
Article in English | WPRIM | ID: wpr-929266

ABSTRACT

Currently, chemoresistance seriously attenuates the curative outcome of liver cancer. The purpose of our work was to investigate the influence of 6-shogaol on the inhibition of 5-fluorouracil (5-FU) in liver cancer. The cell viability of cancer cells was determined by MTT assay. Liver cancer cell apoptosis and the cell cycle were examined utilizing flow cytometry. Moreover, qRT-PCR and western blotting was used to analyse the mRNA and protein expression levels, respectively. Immunohistochemistry assays were used to examine multidrug resistance protein 1 (MRP1) expression in tumour tissues. In liver cancer cells, we found that 6-shogaol-5-FU combination treatment inhibited cell viability, facilitated G0/G1 cell cycle arrest, and accelerated apoptosis compared with 6-shogaol or 5-FU treatment alone. In cancer cells cotreated with 6-shogaol and 5-FU, AKT/mTOR pathway- and cell cycle-related protein expression levels were inhibited, and MRP1 expression was downregulated. AKT activation or MRP1 increase reversed the influence of combination treatment on liver cancer cell viability, apoptosis and cell cycle arrest. The inhibition of AKT activation to the anticancer effect of 6-shogaol-5-FU could be reversed by MRP1 silencing. Moreover, our results showed that 6-shogaol-5-FU combination treatment notably inhibited tumour growth in vivo. In summary, our data demonstrated that 6-shogaol contributed to the curative outcome of 5-FU in liver cancer by inhibiting the AKT/mTOR/MRP1 signalling pathway.


Subject(s)
Humans , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Apoptosis , Catechols , Cell Cycle , Cell Cycle Checkpoints , Cell Line, Tumor , Cell Proliferation , Drug Resistance, Neoplasm , Fluorouracil/pharmacology , Liver Neoplasms/genetics , Multidrug Resistance-Associated Proteins , Proto-Oncogene Proteins c-akt/metabolism , TOR Serine-Threonine Kinases/metabolism
2.
China Pharmacy ; (12): 2603-2608, 2020.
Article in Chinese | WPRIM | ID: wpr-829595

ABSTRACT

OBJECTIVE:To s tudy the protective effect of polydat in complicated with emodin on hyperuricemia (HUA)model rats,and to screen the optimal complication proportion and investigate the potential mechanism. METHODS :SD rats were randomly divided into normal control group ,model group ,benzbromarone group (positive control ,8 mg/kg),polydatin alone group,emodin alone group and drug combination group A ,B,C,with 5 rats in each group of each dosage. Normal control group and model group were given constant volume of 0.3% CMC-Na solution ,administration groups were given relevant medicine intragastrically. Each group was given 0.1 mL/10 g intragastrically once a day ,for consecutive 7 d. Expect for normal control group,other groups were given intraperitoneal injection of potassium oxonate 300 mg/kg 1 h before last medication to induce HUA model. One hour after last medication ,the serum contents of uric acid (UA)were determined in normal control group ,model group,benzbromarone group ,polydatin/alone group (0.625,1.25,2.5,5,10 mg/kg)and drug combination group A [the dose of polydatin+emodin were (0.625+0.625),(1.25+1.25),(2.5+ 2.5),(5 + 5),(10 + 10) mg/kg]. The effect (Fa) and combination index (CI) of above single drug groups and combination groups were calculated by the median effect principle. The dose-effect relationship curves of twocomponents alone or combination were drawn ;Fa-CI curves after simulation were als o drawn to evaluate the effect of two-drug combination. Serum contents of UA in rats were determined and Fa value was calculated in single drug groups and drug combination group B ,C [the dose of polydatin+emodin were (0.625+ 0.625),(0.625+1.25),(0.625+2.5),(0.625+5),(0.625+10)mg/kg and (0.625+0.625),(1.25+0.625),(2.5+0.625),(5+ 0.625),(10+0.625)mg/kg]. The optimal complication proportion of two drugs were screened. The serum contents of xanthine oxidase(XOD)in rats were determined in normal control group ,model group ,benzbromarone group ,polydatin/emodin alone group(10 mg/kg)and the optimal complication proportion groups. The mechanism was analyzed primarily. RESULTS :Compared with normal control group ,the content of UA in model group was increased significantly (P<0.01). Compared with model group , except for 0.625 mg/kg polydatin alone group ,the content of UA in other administration groups were decreased significantly (P< 0.05 or P<0.01). When the two drugs were used alone or in combination ,Fa value was positively correlated with drug dose (intercept>0,correlation coefficient >0.9),and Fa value of the combination group was higher than that of any single drug group ; when the simulated Fa value was more than 15%,the corresponding CI value was less than 1,two-drug combination showed synergistic effect. When the complication proportion of polydatin and emodin was 1∶4,the Fa value (53.10)was similar to that of drug combination group A (53.73),and the dose of them were less [ (0.625+2.5)mg/(kg·d)vs.(2.5+2.5)mg/(kg·d)]. Compared with normal control group ,serum content of XOD in model group was increased significantly (P<0.01);compared with model group,serum content of XOD in administration groups were decreased significantly ,and the optimal complication proportion group was significantly lower than polydatin alone group and emodin alone group (P<0.05 or P<0.01). CONCLUSIONS :The polydatin and emodin used alone or in combination can reduce the serum content of UA in HUA model rats by inhibiting the generation of XOD. They have a certain synergistic effect ,and the optimal complication proportion is 1∶4.

3.
International Eye Science ; (12): 144-145, 2015.
Article in Chinese | WPRIM | ID: wpr-636980

ABSTRACT

? AlM: To compare the two methods for the measurement of glaucoma patients' intraocular pressure ( lOP) between Goldmann applanation tonometer ( GAT) and non-contact tonometer ( NCT) and find the laws of the two methods.?METHODS: The lOP of 108 glaucoma patients ( 206 eyes) were measured by GAT and NCT respectively.?RESULTS: ln 108 glaucoma patients, the average lOP of 206 eyes was 29. 77 ± 10. 27mmHg by GAT and 24. 59 ± 8. 58mmHg by NCT. There was significant difference between GAT and NCT (P<0. 01). The higher of lOP, the difference between GAT and NCT was greater.?CONCLUSlON: The measurement results with NCT were lower than that of GAT. The higher of lOP, the difference between GAT and NCT was greater. lt's better to measure lOP by GAT for the glaucoma patients, in order to avoid the misdiagnosis and mistreatment of glaucoma.

4.
International Eye Science ; (12): 2289-2291, 2014.
Article in Chinese | WPRIM | ID: wpr-637044

ABSTRACT

AlM:To evaluate the clinic efficacy of protein-free calf blood extract ophthalmic gel on healing children dry eye.METHODS: One hundred patients ( 50 patients each group) with children dry eye were divided into two groups randomly: control group was dropped 1g/L sodium hyaluronate eye drop four times per day and experimental group was dropped protein-free calf blood extract ophthalmic gel four times per day. Both groups received the depathogeny treatment at the same time. Symptom scores, Schirmer l test values, tear break-up time ( BUT ) , cornea fluorescein staining scores were recorded on the prior treatment and 30d post-treatment, then they were analyzed. RESULTS:There were statistically significant difference (P CONCLUSlON: There is a clearly beneficial effect of protein-free calf blood extract ophthalmic gel on healing children dry eye.

5.
Chinese Journal of Geriatrics ; (12): 20-23, 2010.
Article in Chinese | WPRIM | ID: wpr-391785

ABSTRACT

Objective To investigate the short and long term therapeutic effects of prostaglandin E1 (PGEl) on diabetic nephropathy (DN). Methods Patients with DN in stage Ⅲ to Ⅴ according to Mogensen criteria were randomly assigned to four groups of PGE1, angiotensin-converting enzyme inhibitor (ACEI), PGE1 + ACEI and control drug. The levels of proteinuria and albuminuria were measured before and 15 days, 6 months and 18 months after treatment. Patients with DN in stage Ⅳ were subdivided into three groups according to proteinuria: early stage IV (protienuria was less than 1.5 g/d), middle stage Ⅳ (protienuria was between 1.5 g/d and 2.5 g/d) and late stage Ⅳ (protienuria was larger than 2.5 g/d). Results Fifteen days after treatment, the levels of proteinuria and albuminuria were significantly decreased compared with pre-treatment in PGE1 and PGE1 + ACEI groups (P<0. 01), and the therapeutic effect was better in PGE1 + ACE1 group than in ACEI group (P<0. 01). Six months after treatment, there were still significant differences in above parameters in patients with DN in stage Ⅲ and Ⅳ between PGE1 + ACEI and PGE1 groups. And for the patients in stage Ⅴ, statistic significance between pre-and post-treatment existed only in PGE1 + ACEI group (P<0. 05). but not in PGE1 and ACEI groups (both P>0. 05). Eighteen months atter treatment, the levels of proteinuria and albuminuria were significantly decreased in patients in stage HI and early stage IV in all treatment groups (P<0. 01). For patients in middle stage IV and late stage Ⅳ , the significant differences still occurred between pre-and post-treatment in PGE1 + ACEI group (P<0. 01 or P<0. 05), and were significantly better than in ACEI group (P<0. 01 or P<0. 05). However, the proteinuria of patients in late stage IV elevated in PGE1 group in post-treatment versus pre-treatment (P<0. 05). Conclusions The short term therapeutic effect of PGE1 is quick and good in patients with DN. The therapeutic effect is much better in patients in stage Ⅲ compared with stage Ⅴ. The combination of PGE1 and ACEI will get better best therapeutic effect than PGE1 or ACEI alone in long term.

6.
Journal of Southern Medical University ; (12): 482-485, 2010.
Article in Chinese | WPRIM | ID: wpr-355095

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the therapeutic effect of prostaglandin E1 (PGEl) on diabetic nephropathy (DN) after a one-year treatment.</p><p><b>METHODS</b>According to Mogensen DN diagnostic criteria, the patients were divided into DN stages III, IV and V groups. Patients in stage IV nephropathy were subdivided into three groups according to the proteinuria, namely early stage IV (protienuria less than 1.5 g/day), mid-stage IV (protienuria between 1.5 and 2.5 g/day) and late stage IV (protienuria above 2.5 g/day). The patients were randomly given PGEl, PGEl plus angiotensin-converting enzyme inhibitor (ACEI), ACEI mono-therapy or basal treatment (control group). Proteinuria and albuminuria were measured before and at 15 days and 1 year of the treatment.</p><p><b>RESULTS</b>In the patients in DN stages III and early stage IV, proteinuria and albuminuria decreased significantly after 15 days and 1 year of treatment with PGEl+ACEI and PGEl (P<0.01), and the decrements were greater than that in patients receiving ACEI only (P<0.01 or P<0.05). In the patients in mid- and late stage IV nephropathy, proteinuria and albuminuria decreased significantly in PGEl+ACEI group after 15 days and 1 year of treatment (P<0.01), showing greater decrement than in ACEI group (P<0.01 ). Proteinuria and albuminuria decreased significantly in PGEl group after 15 days of treatment (P<0.01), but remained higher than that in ACEI group at one year (P<0.05). In the patients with stage V nephropathy, significant proteinuria and albuminuria reduction occurred in PGEl+ACEI and PGEl groups at 15 days (P<0.01) with a greater decrement than that in ACEI group (P<0.01 or P<0.05). In PGEl+ACEI group, proteinuria and albuminuria showed no significant changes at one year but were lower than those in ACEI group (P<0.05). Proteinuria and albuminuria increased significantly in ACEI and PGEl group after the treatment but were comparable between the two groups (P<0.05).</p><p><b>CONCLUSIONS</b>The therapeutic effects are much better in patients with stage III nephropathy than in those in stage V. The combination of PGEl and ACEI produces stronger therapeutic effects than PGE1 or ACEI alone even at the one-year follow up.</p>


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Albuminuria , Urine , Alprostadil , Therapeutic Uses , Angiotensin-Converting Enzyme Inhibitors , Therapeutic Uses , Diabetic Nephropathies , Drug Therapy , Drug Therapy, Combination , Follow-Up Studies
7.
Chinese Journal of Geriatrics ; (12): 498-501, 2008.
Article in Chinese | WPRIM | ID: wpr-399763

ABSTRACT

Objective To investigate the effects of prostaglandin E1(PGEl)in improving proteinuria and albuminuria in the elderly people with diabetic nephropathy(DN). Methods Patients including stage Ⅲ,stage Ⅳ and stage Ⅴ were divided into four groups:conventional therapy group,PGE1 group,PGE1+ACEI group and ACEI group.Proteinuria and albuminuria were measured before and after treatment for 15 days,3 months,6 months. Results (1)In the DN patients in stage Ⅲ and stage Ⅳ (proteinuria<2.5 g/d),the proteinuria and albuminuria descended markedly in PGE1+ACEI and PGEl group(P<0.01).It was better than that in eonventionaI therapy and ACEI group.(2)In the DN patients in stage Ⅳ(proteinuria>2.5 g/d),proteinuria and albuminuria were not changed significantly after 3 months and 6 months in PGE1+ACEI and PGE1 group,but they were increased in conventional group(P<0.05).(3)In the DN patients in stage Ⅴ,the proteinuria and albuminuria were not changed much after 1 5 days,3 months and 6 months(P<0.05).The proteinuria and albuminuria were increased by more than 10 percent(P<0.01)in the conventional group after 3 and 6 months. Conclusions The therapeutic effects of PGE1 are obvious.Early treatment of nephropathy will get a better improvement in patients with diabetic nephropathy.

8.
Chinese Acupuncture & Moxibustion ; (12): 545-547, 2005.
Article in Chinese | WPRIM | ID: wpr-258990

ABSTRACT

<p><b>OBJECTIVE</b>To find out a method for increasing clinical therapeutic effect on Bell palsy at acute stage.</p><p><b>METHODS</b>Ninety cases of Bell palsy were randomly divided into an observation group, a control group I and a control group II, 30 cases in each group. They were treated respectively with acupuncture plus exercise therapy, simple acupuncture therapy, and simple exercise therapy, and their therapeutic effects were observed.</p><p><b>RESULTS</b>The cured rate was 66.7% in the observation group, 53.3% in the control group I and 46.70% in the control group II, the observation group being better than the two control groups (P<0.05).</p><p><b>CONCLUSION</b>Acupuncture by stage combined with exercise therapy can increase the therapeutic effect on Bell palsy at acute stage, and it is a better therapy for Bell palsy.</p>


Subject(s)
Humans , Acupuncture Therapy , Bell Palsy , Therapeutics , Combined Modality Therapy , Exercise Therapy , Facial Paralysis
9.
Chinese Journal of Integrated Traditional and Western Medicine ; (12): 908-910, 2003.
Article in Chinese | WPRIM | ID: wpr-320279

ABSTRACT

<p><b>OBJECTIVE</b>To observe the effect of Fuzheng Yiliu Granule (FZYLG) on cell cycle and nuclear transcription factor-kappa B (NF-kappa B) in tissue of esophageal-gastric carcinoma.</p><p><b>METHODS</b>Seventy-six patients with esophageal gastric carcinoma were randomly divided into two groups, the FZYLG group and the control group. FZYLG was given to the former for 15 days. The tumor tissue in both groups was resected and cell cycle and apoptosis rate as well as NF-kappa B were determined by flowcytometry.</p><p><b>RESULTS</b>Level of NF-kappa B in the treated group was significantly higher than that in the control group (P < 0.05). In the treated group, the percentage of G0/G1 stage cells were significantly increased and that of S stage significantly decreased (both P < 0.05). At the same time, obvious cell apoptosis was found in the treated group, the apoptosis rate of which was significantly higher than that in the control group (P < 0.01).</p><p><b>CONCLUSION</b>FZYLG can increase the NF-kappa B expression, block the proliferation to promote the apoptosis of tumor cells.</p>


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Adenocarcinoma , Drug Therapy , Pathology , Carcinoma, Squamous Cell , Drug Therapy , Pathology , Cell Cycle , Drugs, Chinese Herbal , Therapeutic Uses , Esophageal Neoplasms , Drug Therapy , Pathology , NF-kappa B , Metabolism , Phytotherapy , Stomach Neoplasms , Drug Therapy , Pathology
10.
Chinese Journal of Biotechnology ; (12): 112-116, 2002.
Article in Chinese | WPRIM | ID: wpr-231385

ABSTRACT

5' and 3' flanking region of ovine BLG were amplified from sheep genomic DNA according to the published whole sequence of ovine BLG and cloned to pGEM-T vector correspondently. By partially sequencing, the sequences of BLG 5' and 3' flanking were the same as that of publication completely. The recombinant structure used to direct exogenous gene especially to express in mammary gland was constructed by joining 4.2 kb 5' flanking with 2.1 kb 3' flanking. In order to assess the efficiency of BLG regulatory elements, green fluorescent protein (GFP) gene as a reporter was fused with BLG construct and transfected the mammary epithelial cells (TD47). Through observation under UV microscope and detection by fluorometer, it is demonstrated that the GFP has been successfully expressed in TD47 cell line. By virtue of direct observation and quantitative analysis, the BLG-GFP construct can be served as a model for the quick assessment of mammary gland expression construct.


Subject(s)
Animals , 3' Flanking Region , Genetics , 5' Flanking Region , Genetics , Breast , Cell Biology , Cell Line , Cloning, Molecular , Gene Expression Regulation , Genes, Reporter , Green Fluorescent Proteins , Lactoglobulins , Genetics , Luminescent Proteins , Genetics , Sheep
SELECTION OF CITATIONS
SEARCH DETAIL